Literature DB >> 26541272

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Zijun Y Xu-Monette1, Bouthaina S Dabaja2, Xiaoxiao Wang1, Meifeng Tu1, Ganiraju C Manyam3, Alexander Tzankov4, Yi Xia1, Li Zhang3, Ruifang Sun1, Carlo Visco5, Karen Dybkaer6, Lihui Yin1, April Chiu7, Attilio Orazi8, Youli Zu9, Govind Bhagat10, Kristy L Richards11, Eric D Hsi12, William W L Choi13, J Han van Krieken14, Jooryung Huh15, Maurilio Ponzoni16, Andrés J M Ferreri16, Michael B Møller17, Ben M Parsons18, Xiaoying Zhao19, Jane N Winter20, Miguel A Piris21, Timothy J McDonnell1, Roberto N Miranda1, Yong Li22, L Jeffrey Medeiros1, Ken H Young1,23.   

Abstract

MYC dysregulation, including MYC gene rearrangement and Myc protein overexpression, is of increasing clinical importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance of rearrangement vs overexpression remain to be refined. Gaining knowledge about the tumor biology associated with MYC dysregulation is important to understand the roles of MYC and MYC-associated biology in lymphomagenesis. In this study, we determined MYC rearrangement status (n=344) and Myc expression (n=535) in a well-characterized DLBCL cohort, individually assessed the clinical and pathobiological features of patients with MYC rearrangement and Myc protein overexpression, and analyzed the prognosis and gene expression profiling signatures associated with these MYC abnormalities in germinal center B-cell-like and activated B-cell-like DLBCL. Our results showed that the prognostic importance of MYC rearrangement vs Myc overexpression is significantly different in germinal center B-cell-like vs activated B-cell-like DLBCL. In germinal center B-cell-like DLBCL, MYC-rearranged germinal center B-cell-like DLBCL patients with Myc overexpression significantly contributed to the clinical, biological, and prognostic characteristics of the overall Myc-overexpressing germinal center B-cell-like DLBCL group. In contrast, in activated B-cell-like DLBCL, the occurrence, clinical and biological features, and prognosis of Myc overexpression were independent of MYC rearrangement. High Myc levels and Myc-independent mechanisms, either tumor cell intrinsic or related to tumor microenvironment, conferred significantly worse survival to MYC-rearranged germinal center B-cell-like DLBCL patients, even among Myc(high)Bcl-2(high) DLBCL patients. This study provides new insight into the tumor biology and prognostic effects associated with MYC dysregulation and suggest that detection of both MYC translocations and evaluation of Myc and Bcl-2 expression is necessary to predict the prognosis of DLBCL patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26541272     DOI: 10.1038/modpathol.2015.118

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  57 in total

1.  Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

Authors:  Gustaaf W van Imhoff; Evert-Jan G Boerma; Bronno van der Holt; Ed Schuuring; Leo F Verdonck; Hanneke C Kluin-Nelemans; Philip M Kluin
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

2.  MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?

Authors:  Catherine Thieblemont; Josette Brière
Journal:  Blood       Date:  2013-03-21       Impact factor: 22.113

3.  Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

Authors:  T Holien; T K Våtsveen; H Hella; C Rampa; G Brede; L A G Grøseth; M Rekvig; M Børset; T Standal; A Waage; A Sundan
Journal:  Leukemia       Date:  2011-09-23       Impact factor: 11.528

4.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

5.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

6.  BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.

Authors:  Maria Grazia Tibiletti; Vittoria Martin; Barbara Bernasconi; Barbara Del Curto; Lorenza Pecciarini; Silvia Uccella; Giancarlo Pruneri; Maurillio Ponzoni; Luca Mazzucchelli; Giovanni Martinelli; Andrés J Ferreri; Graziella Pinotti; Andrea Assanelli; Marta Scandurra; Claudio Doglioni; Emanuele Zucca; Carlo Capella; Francesco Bertoni
Journal:  Hum Pathol       Date:  2009-01-13       Impact factor: 3.466

7.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

8.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Zijun Y Xu-Monette; Michael B Møller; Alexander Tzankov; Santiago Montes-Moreno; Wenwei Hu; Ganiraju C Manyam; Louise Kristensen; Lei Fan; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Lin Wu; Xiaoying Zhao; Carlos E Bueso-Ramos; Sa A Wang; Ronald S Go; Yong Li; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

Review 10.  MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Authors:  Qingqing Cai; L Jeffrey Medeiros; Xiaolu Xu; Ken H Young
Journal:  Oncotarget       Date:  2015-11-17
View more
  21 in total

Review 1.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Authors:  Zijun Y Xu-Monette; Qipan Deng; Ganiraju C Manyam; Alexander Tzankov; Ling Li; Yi Xia; Xiao-Xiao Wang; Dehui Zou; Carlo Visco; Karen Dybkær; Jun Li; Li Zhang; Han Liang; Santiago Montes-Moreno; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Ben M Parsons; Michael B Møller; Sa A Wang; Roberto N Miranda; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Yong Li; Ken H Young
Journal:  Clin Cancer Res       Date:  2016-02-29       Impact factor: 12.531

3.  AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Authors:  Jinfen Wang; Zijun Y Xu-Monette; Kausar J Jabbar; Qi Shen; Ganiraju C Manyam; Alexandar Tzankov; Carlo Visco; Jing Wang; Santiago Montes-Moreno; Karen Dybkær; Wayne Tam; Govind Bhagat; Eric D Hsi; J Han van Krieken; Maurilio Ponzoni; Andrés J M Ferreri; Shi Wang; Michael B Møller; Miguel A Piris; L Jeffrey Medeiros; Yong Li; Lan V Pham; Ken H Young
Journal:  Am J Pathol       Date:  2017-06-13       Impact factor: 4.307

4.  Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.

Authors:  Miguel Gallardo; Prerna Malaney; Marisa J L Aitken; Xiaorui Zhang; Todd M Link; Vrutant Shah; Sanzhar Alybayev; Meng-Han Wu; Laura R Pageon; Huaxian Ma; Rodrigo Jacamo; Li Yu; Zijun Y Xu-Monette; Haley Steinman; Hun Ju Lee; Dos Sarbassov; Inmaculada Rapado; Michelle C Barton; Joaquin Martinez-Lopez; Carlos Bueso-Ramos; Ken H Young; Sean M Post
Journal:  J Natl Cancer Inst       Date:  2020-01-01       Impact factor: 13.506

5.  Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.

Authors:  Zijun Y Xu-Monette; Li Wei; Xiaosheng Fang; Qingyan Au; Harry Nunns; Hua You; Máté Nagy; Alexandar Tzankov; Feng Zhu; Carlo Visco; Govind Bhagat; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Fredrick B Hagemeister; Xiaoping Sun; Xin Han; Heounjeong Go; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Yong Li; Bing Xu; Maher Albitar; Ken H Young
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 13.801

Review 6.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

7.  NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Authors:  Qingqing Cai; Meifeng Tu; Zijun Y Xu-Monette; Ruifang Sun; Ganiraju C Manyam; Xiaolu Xu; Alexander Tzankov; Eric D Hsi; Michael B Møller; L Jeffrey Medeiros; Chi Young Ok; Ken H Young
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

8.  Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.

Authors:  L Deng; Z Y Xu-Monette; S Loghavi; G C Manyam; Y Xia; C Visco; J Huh; L Zhang; Q Zhai; Y Wang; L Qiu; K Dybkær; A Chiu; A M Perry; S Zhang; A Tzankov; H Rao; J Abramson; A R Sohani; M Xu; E D Hsi; J Zhu; M Ponzoni; S Wang; Ling Li; M Zhang; A J M Ferreri; B M Parsons; Y Li; M A Piris; L J Medeiros; K H Young
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

9.  Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Authors:  Qing Ye; Zijun Y Xu-Monette; Alexandar Tzankov; Lijuan Deng; Xiaoxiao Wang; Ganiraju C Manyam; Carlo Visco; Santiago Montes-Moreno; Li Zhang; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Ben M Parsons; Michael B Møller; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Shimin Hu; Ken H Young
Journal:  Oncotarget       Date:  2016-01-19

10.  Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.

Authors:  Manman Deng; Zijun Y Xu-Monette; Lan V Pham; Xudong Wang; Alexandar Tzankov; Xiaosheng Fang; Feng Zhu; Carlo Visco; Govind Bhagat; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; Hua You; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; Fredrick Hagemeister; J Han van Krieken; Miguel A Piris; Jane N Winter; Yong Li; Bing Xu; Phillip Liu; Ken H Young
Journal:  Mol Cancer Res       Date:  2020-11-05       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.